24Aug 2023
Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts

This study investigated targeting KRAS-mutated metastatic colorectal cancers using combined trametinib and cetuximab. In patient-derived xenograft models, this approach induced stable disease or partial response in 74% compared to 24% with trametinib alone. Prolonged response and low secondary resistance were observed in partial response cases.

  • #oncology

Like

Save

Share